JAK2 and cancer: Janus kinase 2 (JAK2), phosphoinositide 3-kinase inhibitors/protein kinase B (PI3K/Akt) and extracellular related signal kinases (ERK) signaling was inhibited in pancreatic [34] and liver [1] cancer.